Rezultati pretraživanja
  1. prije 18 sati

    Interested candidates can ping me @ Hetero Biopharma

  2. prije 27 minuta

    Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - 

  3. . of discusses the emergence of in oncology and how he anticipates they will change the paradigm

  4. prije 7 sati

    BREAKING: ⁦⁩ announces spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran.

  5. prije 8 sati

    How much does your state save? In 2018, generic prescription medicines saved $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved:

  6. prije 8 sati
    Odgovor korisniku/ci

    check out my latest post on spin out of hodge-podge product lines including licensed from Samsung Bioepis. Would make sense for to do another spinout of then do a M&E with with better marketing org. Eliminate duplicate R&D.

  7. prije 8 sati

    -- new hodge-podge spin out includes marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure co and buy with better marketing org. Eliminate duplicate R&D (even I can make a bull case for )

  8. prije 12 sati
    Odgovor korisniku/ci

    are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here.

  9. Looking for information about and ? Take a peek at our sheet, and learn why we advocate for patient-doctor choice 👨‍⚕️🏥👩‍⚕️.

  10. prije 13 sati
  11. prije 14 sati

    Do you ever wonder where the US market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the industry.

  12. prije 15 sati

    Go Behind the Scenes at Teva’s state-of-the-art facility in Ulm, Germany, and meet the experts who are advancing more treatment options for patients

  13. prije 16 sati

    Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and into New Company (“NewCo”)

  14. Having an intention to prove yourself to the world? Let's Euro Biosimilars 2020 learn and Explore . for . YoungResearcher #2020

  15. 5. velj

    China’s Biosimilars Commercialized at an Impressive Speed. A comparison of the biosimilar accessibility in China, the EU, and the U.S.

  16. 4. velj

    FDA and FTC Say They Will Work Collaboratively to Deter Anticompetitive Behavior: Actions Speak Louder Than Words

  17. 4. velj
  18. 3. velj
    Odgovor korisnicima i sljedećem broju korisnika:

    IMHO, your paper is the most important paper on in 2019. It is THE counter to argument for heavy regulation (vs competition) of a biologic therapeutic class once the reference drug loses it patents.

  19. 3. velj
    Odgovor korisnicima i sljedećem broju korisnika:

    You state that are list priced 15% to 35% less than reference drug...implying that are cheaper than reference drugs. You should do more work on getting comparisons of net prices after rebates in the commercial market and report on that

  20. 1. velj

    With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.